Research & Studies
The major GLP-1 trials generate headlines that often misrepresent the data. Our research coverage translates designs, primary endpoints, and hazard ratios into plain language: SURMOUNT & SURPASS for tirzepatide, SELECT and SOUL for semaglutide cardiovascular outcomes, GLP-1 and cancer risk evidence. Without the marketing spin.
Does Semaglutide Cut Heart Attack Risk?
A run of large trials reframed semaglutide — from a blood-sugar drug, to a weight drug, to a proven cardiovascular…
Latest in Research & Studies
Do GLP-1 Drugs Cause Cancer? Honest Answer.
A boxed warning, scary headlines, anxious social-media posts. The real cancer evidence on GLP-1 drugs is more nuanced — and…
Compounded Semaglutide from $147/month
LegitScript-certified · 503A US pharmacy · 1-2 day shipping · Available in 48 states